CD19 and acute lymphoblastic leukemia: In another case, a multi-step regimen for KMT2A-rearranged ALL—including palbociclib, chemotherapy, blinatumomab consolidation, and CD19 CAR-T infusion—led to deep molecular remission without added toxicity (229), suggesting that sequential regimens can extend therapeutic benefit even in poor-risk cytogenetics.